These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Chimeric Antigen Receptors for Cancer Immunotherapy. Geldres C; Savoldo B; Dotti G Methods Mol Biol; 2016; 1393():75-86. PubMed ID: 27033217 [TBL] [Abstract][Full Text] [Related]
10. The basic principles of chimeric antigen receptor design. Sadelain M; Brentjens R; Rivière I Cancer Discov; 2013 Apr; 3(4):388-98. PubMed ID: 23550147 [TBL] [Abstract][Full Text] [Related]
11. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Di S; Li Z Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709 [TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860 [TBL] [Abstract][Full Text] [Related]
13. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181 [TBL] [Abstract][Full Text] [Related]
14. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. Harris DT; Kranz DM Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086 [TBL] [Abstract][Full Text] [Related]
15. Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy. Zhang M; Zhang DB; Shi H Immunotherapy; 2017 Sep; 9(10):851-861. PubMed ID: 28877629 [TBL] [Abstract][Full Text] [Related]
16. Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases. Hombach A; Pohl C; Reinhold U; Abken H Hybridoma; 1999 Feb; 18(1):57-61. PubMed ID: 10211789 [TBL] [Abstract][Full Text] [Related]
17. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. Chen D; Yang J Transl Res; 2017 Sep; 187():11-21. PubMed ID: 28641074 [TBL] [Abstract][Full Text] [Related]
18. CARTs for Solid Tumors: Feasible or Infeasible? Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706 [TBL] [Abstract][Full Text] [Related]
19. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes. Hammill JA; Afsahi A; Bramson JL; Helsen CW Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020 [TBL] [Abstract][Full Text] [Related]
20. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells. Yang QY; Yang JD; Wang YS Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]